• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Cipla Ltd.
    13 Jul 2025
    1499.40
    -0.68%
    Cipla To Take On Eli Lilly, Novo Nordisk With Entry Into India's Weigh-Loss Drug Sector
    Cipla To Take On Eli Lilly, Novo Nordisk With Entry Into India's Weigh-Loss Drug Sector
    NDTV Profit
    Cipla is preparing to enter the weight-loss drug making sector, heating the competition with US-based Eli Lilly & Co and Danish firm Novo Nordisk.
    Copy LinkShare onShare on Share on Share on
    Cipla Ltd. is trading above its 200 day SMA of 1495.0
    Cipla gears up to enter weight management segment in India
    Business Line | 13 Jul 2025 1 more
    Cipla to enter weight management segment in India: MD & Global CEO Vohra
    Business Standard | 13 Jul 2025
    logo
    Glenmark Pharmaceuticals Ltd.
    12 Jul 2025
    Dividend
    1971.70
    -2.91%
    Glenmark surges 20% after major drug licensing deal with AbbVie
    Glenmark surges 20% after major drug licensing deal with AbbVie
    Economic Times
    Glenmark Pharmaceuticals shares surged following a significant licensing agreement. Ichnos Glenmark Innovation partnered with AbbVie for a drug targeting oncology and autoimmune diseases. Glenmark will receive $700 million upfront. Potential milestone payments could reach $1.2 billion. Future sales will also generate revenue for Glenmark. Analysts predict a positive re-rating of the stock due to this deal.
    Copy LinkShare onShare on Share on Share on
    Geojit BNP Paribas increased Accumulate price target of Glenmark Pharmaceuticals Ltd. to 2306.0 on 09 Sep, 2025.
    logo
    Wockhardt Ltd.
    11 Jul 2025
    High Loss High Volume
    1336.50
    -9.46%
    Wockhardt exits US generics biz, to focus on innovative portfolio
    Business Standard
    Wockhardt exits the US generics market after years of losses, shifting focus to new antibiotic drug discovery and biologicals, including insulin, to create long-term value.
    Copy LinkShare onShare on Share on Share on
    Wockhardt Ltd. is trading below all available SMAs
    Wockhardt to exit its US generics business
    Business Line | 11 Jul 2025 1 more
    Wockhardt exits US generics business, files for liquidation of subsidiaries
    Business Standard | 11 Jul 2025
    logo
    Glenmark Pharmaceuticals Ltd.
    11 Jul 2025
    Dividend
    1971.70
    -2.91%
    Glenmark Pharma soars 10%, hits 52-week high on cancer drug licensing deal
    Business Standard
    At 09:30 AM, Glenmark Pharma shares were trading at 2,094.40, up by 10 per cent on the National Stock Exchange.
    Copy LinkShare onShare on Share on Share on
    Geojit BNP Paribas increased Accumulate price target of Glenmark Pharmaceuticals Ltd. to 2306.0 on 09 Sep, 2025.
    Glenmark Pharma Shares Hit Life High After License Deal With AbbVie For Cancer Drug
    NDTV Profit | 11 Jul 2025 4 more
    Glenmark Share Price Live: Glenmark Pharma locked in upper circuit after its arm's mega ISB 2001 deal
    Business Line | 11 Jul 2025
    Glenmark Pharma's Mega Deal With AbbVie Has Brokerages Mixed
    NDTV Profit | 11 Jul 2025
    Glenmark subsidiary IGI inks $700-m deal on cancer drug candidate with multinational AbbVie
    Business Line | 10 Jul 2025
    Glenmark Pharma's unit, Abbvie sign global licensing deal for cancer drug
    Business Standard | 10 Jul 2025
    logo
    Mankind Pharma Ltd.
    11 Jul 2025
    2482.90
    -1.71%
    Mankind Pharma Gets Target Price Hike Why Jefferies Calls It Top Pick
    Mankind Pharma Gets Target Price Hike Why Jefferies Calls It Top Pick
    NDTV Profit
    Jefferies anticipates that the first and second quarters will be pivotal for Mankind Pharma, with India Rx growth normalising in the second half of the fiscal.
    Copy LinkShare onShare on Share on Share on
    Mankind Pharma Ltd. has an average target of 2840.50 from 2 brokers.
    Stock Market Live Updates 11 July 2025: Stock to buy today: Mankind Pharma
    Business Line | 11 Jul 2025 2 more
    Today's Stock Recommendation: July 11, 2025
    Business Line | 11 Jul 2025
    Stock to buy today: Mankind Pharma (2,543) BUY
    Business Line | 11 Jul 2025
    logo
    Shilpa Medicare Ltd.
    10 Jul 2025
    Bonus
    771.85
    -2.63%
    Here's why Shilpa Medicare share price is buzzing in trade today; details
    Business Standard
    Shilpa Medicare shares rose today after the company secured GMP certification from Saudi Arabia's SFDA for its Unit VI facility in Dabaspet, Bengaluru.
    Copy LinkShare onShare on Share on Share on
    Shilpa Medicare Ltd. is trading below all available SMAs
    logo
    Emcure Pharmaceuticals Ltd.
    10 Jul 2025
    1284.20
    -3.14%
    Emcure Pharma rises over 2% as USFDA issues Form 483 with Zero observations
    Business Standard
    Emcure Pharma share price rose in trade after the company announced that United States Food and Drug Administration (USFDA) issued Form 483 with zero observations for its Sanand, Ahmedabad unit.
    Copy LinkShare onShare on Share on Share on
    Emcure Pharmaceuticals Ltd. is trading below its 30 day SMA of 1388.6
    logo
    Lupin Ltd.
    10 Jul 2025
    1919.80
    -2.23%
    Lupin, Zentiva Group ink agreement to commercialise biosimilar Certolizumab Pegol
    Business Line
    Both parties will invest in the development of the new biosimilar
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.
    logo
    Lupin Ltd.
    09 Jul 2025
    1919.80
    -2.23%
    Lupin share pops 2% on licencing and supply agreement with Zentiva; details
    Business Standard
    Lupin's share price rose in trade today after the company announced a licensing and supply agreement with Zentiva, k.s., for the commercialisation of its biosimilar Certolizumab Pegol.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.
    logo
    Laurus Labs Ltd.
    09 Jul 2025
    High Loss High Volume
    832.30
    -7.15%
    Glenmark, Laurus Lab: Will Trump's 200% tariff threat derail pharma stocks?
    Business Standard
    Donald Trump threatens of a potential 200% tariff on pharma imports; can this derail the rally in pharma shares, which have gained up to 50% in 3 months. Here's what the technical charts suggest.
    Copy LinkShare onShare on Share on Share on
    Laurus Labs Ltd.'s price crossed below 30Day SMA today
    more
    loading
    Trendlyne Logo Trendlyne
    Stay ahead of the market
    Markets Today
    • Nifty 50 today
    • Sensex today
    • Latest Quarterly results
    • FII & DII data today
    Dashboard
    • Industry & Sector analysis
    • ETFs
    • Mutual Funds
    • Bullish & Bearish spread
    • Global Indices
    Tools
    • Compare stocks
    • Widgets
    • Data Downloader
    • Excel Connect
    IPOs
    • Dashboard (Mainboard & SME)
    • Upcoming IPOs
    • Recently Listed IPOs
    • Most Successful IPOs
    Upcoming IPOs
    • Jinkushal Industries
    • Chatterbox Technologies
    • Rukmani Devi Garg Agro Impex
    Quick Links
    • Contact us
    • Blogs
    • FAQs
    Company
    • Privacy
    • Terms of Use
    • Disclaimer
    Trendlyne Products
    • Starfolio
    • SmartOptions
    • Trendlyne US Global
    Get Mobile App
    • Android
    • iOS

    Copyright © 2025 Giskard Datatech Pvt Ltd (RA SEBI Reg No: INH000022507)